<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452452</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-3002</org_study_id>
    <nct_id>NCT00452452</nct_id>
  </id_info>
  <brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children</brief_title>
  <official_title>A Phase 3 Open-label Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Older Infants and Children Who Are Naive to Previous Vaccination With Pneumococcal Conjugate Vaccine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and immunogenicity of a
      13-valent Pneumococcal conjugate vaccine (13vPnC) in older infants and children who have not
      previously been immunized with Pneumococcal vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination</measure>
    <time_frame>28 to 42 days after vaccination 3 for Group 1 (13 to &lt;17 months of age), after vaccination 2 for Group 2 (14 to &lt;26 months of age), and after vaccination 1 for Group 3 (26 to &lt;73 months of age).</time_frame>
    <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration (GMC) After Vaccination in 13vPnC Groups</measure>
    <time_frame>28 to 42 days after vaccination 3 for Group 1 (13 to &lt;17 months of age), after vaccination 2 for Group 2 (14 to &lt;26 months of age), and after vaccination 1 for Group 3 (26 to &lt;73 months of age).</time_frame>
    <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Systemic events (fever ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged from 7 months to &lt;72 months at time of enrollment.

          2. Available for entire study period and whose parent/legal guardian could be reached by
             telephone.

          3. Healthy as determined by medical history, physical examination, and judgment of the
             investigator.

          4. Parent/legal guardian had to be able to complete all relevant study procedures during
             subject participation.

        Exclusion Criteria:

          1. Previous vaccination with licensed or investigational pneumococcal vaccine.

          2. A previous anaphylactic reaction to any vaccine or vaccine-related component.

          3. Contraindication to vaccination with pneumococcal vaccine.

          4. Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          5. Known or suspected immune deficiency or suppression.

          6. History of culture-proven invasive disease caused by S pneumoniae.

          7. Major known congenital malformation or serious chronic disorders.

          8. Significant neurological disorder or history of seizure including febrile seizure, or
             significant stable or evolving disorders such as cerebral palsy, encephalopathy,
             hydrocephalus, or other significant disorders. Does not include resolving syndromes
             due to birth trauma such as Erb palsy.

          9. Receipt of blood products or gamma-globulin (including monoclonal antibodies) in the
             last 3 months.

         10. Participation in another investigational or interventional trial. Participation in
             purely observational studies is acceptable.

         11. Child is a direct descendant (child or grandchild) of a member of the study site
             personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Poland: WPWZMED@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-316</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-503</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leczna</city>
        <zip>21-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>91-738</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oborniki Salskie</city>
        <zip>55-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Proznan</city>
        <zip>61-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2007</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>July 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2012</results_first_posted>
  <disposition_first_submitted>January 21, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 1, 2009</disposition_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in Poland from July 2007 to September 2007.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into the study according to inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC 7 to &lt;12 Months of Age</title>
          <description>Participants 7 to less than (&lt;) 12 months of age with 0 prior doses of 7-valent pneumococcal conjugate vaccine (Prevnar) received a total of 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC); the first two at least 28 days apart (infant series) and the third single IM 0.5 mL dose of 13vPnC at 12 to 16 months of age (toddler dose), at least 46 days after last infant dose.</description>
        </group>
        <group group_id="P2">
          <title>13vPnC 12 to &lt;24 Months of Age</title>
          <description>Participants 12 to &lt; 24 months of age with 0 prior dose of 7-valent pneumococcal conjugate vaccine (Prevnar) received a total of 2 single IM 0.5 mL doses of 13vPnC at least 56 days apart.</description>
        </group>
        <group group_id="P3">
          <title>13vPnC 24 to &lt; 72 Months of Age</title>
          <description>Participants 24 to &lt; 72 months of age with 0 prior doses of 7-valent pneumococcal conjugate vaccine (Prevnar) received a single IM 0.5 mL dose of 13vPnC.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC 7 to &lt;12 Months of Age</title>
          <description>Participants 7 to less than (&lt;) 12 months of age with 0 prior doses of 7-valent pneumococcal conjugate vaccine (Prevnar) received a total of 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC); the first two at least 28 days apart (infant series) and the third single IM 0.5 mL dose of 13vPnC at 12 to 16 months of age (toddler dose), at least 46 days after last infant dose.</description>
        </group>
        <group group_id="B2">
          <title>13vPnC 12 to &lt;24 Months of Age</title>
          <description>Participants 12 to &lt; 24 months of age with 0 prior dose of 7-valent pneumococcal conjugate vaccine (Prevnar) received a total of 2 single IM 0.5 mL doses of 13vPnC at least 56 days apart.</description>
        </group>
        <group group_id="B3">
          <title>13vPnC 24 to &lt; 72 Months of Age</title>
          <description>Participants 24 to &lt; 72 months of age with 0 prior doses of 7-valent pneumococcal conjugate vaccine (Prevnar) received a single IM 0.5 mL dose of 13vPnC.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="112"/>
            <count group_id="B3" value="153"/>
            <count group_id="B4" value="355"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.7" spread="1.6"/>
                    <measurement group_id="B2" value="17.6" spread="3.5"/>
                    <measurement group_id="B3" value="42.0" spread="13.1"/>
                    <measurement group_id="B4" value="25.9" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination</title>
        <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>28 to 42 days after vaccination 3 for Group 1 (13 to &lt;17 months of age), after vaccination 2 for Group 2 (14 to &lt;26 months of age), and after vaccination 1 for Group 3 (26 to &lt;73 months of age).</time_frame>
        <population>Evaluable immunogenicity (per protocol) population who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate immunoglobulin G (IgG) antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC 7 to &lt;12 Months of Age</title>
            <description>Participants 7 to less than (&lt;) 12 months of age with 0 prior doses of 7-valent pneumococcal conjugate vaccine (Prevnar) received a total of 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC); the first two at least 28 days apart (infant series) and the third single IM 0.5 mL dose of 13vPnC at 12 to 16 months of age (toddler dose), at least 46 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC 12 to &lt;24 Months of Age</title>
            <description>Participants 12 to &lt; 24 months of age with 0 prior dose of 7-valent pneumococcal conjugate vaccine (Prevnar) received a total of 2 single IM 0.5 mL doses of 13vPnC at least 56 days apart.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC 24 to &lt; 72 Months of Age</title>
            <description>Participants 24 to &lt; 72 months of age with 0 prior doses of 7-valent pneumococcal conjugate vaccine (Prevnar) received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination</title>
          <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate immunoglobulin G (IgG) antibody concentration to the given serotype.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n= 84,110,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.3" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=83,110,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.3" lower_limit="96.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n= 83,104,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.0" lower_limit="94.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.6" lower_limit="95.2" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n= 84,108,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="88.1" lower_limit="81.5" upper_limit="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n= 83,109,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.7" lower_limit="95.3" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=84,110,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="91.7" upper_limit="99.7"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.0" lower_limit="94.2" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n= 84,110,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="92.7" lower_limit="86.2" upper_limit="96.8"/>
                    <measurement group_id="O3" value="93.4" lower_limit="88.2" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n= 83,108,149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="96.6" lower_limit="92.3" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n= 83,108,149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="97.3" lower_limit="93.3" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n= 84,107,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="91.7" upper_limit="99.7"/>
                    <measurement group_id="O2" value="99.1" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.7" lower_limit="95.3" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n= 84,110,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.2" lower_limit="93.6" upper_limit="99.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n= 84,108,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.3" lower_limit="96.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=84,110,150</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
        <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all participants who received at least 1 dose of vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 - Dose 1</title>
            <description>Participants 7 to less than (&lt;) 12 months of age with 0 prior doses of Prevnar received a single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC)(infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 - Dose 1</title>
            <description>Participants 12 to &lt; 24 months of age with 0 prior doses of Prevnar received a single IM 0.5 mL doses of 13vPnC (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 - Dose 1</title>
            <description>Participants 24 to &lt; 72 months of age with 0 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series).</description>
          </group>
          <group group_id="O4">
            <title>13vPnC Group 1 - Dose 2</title>
            <description>Participants 7 to less than (&lt;) 12 months of age received a second single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days after the first (infant series).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Group 2 - Dose 2</title>
            <description>Participants 12 to &lt; 24 months of age received a second single IM 0.5 mL doses of 13vPnC at least 56 days from the first (infant series).</description>
          </group>
          <group group_id="O6">
            <title>13vPnC Group 1 - Dose 3</title>
            <description>Participants received a third single IM 0.5 mL dose of 13vPnC at 12 to 16 months of age (toddler dose), at least 46 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
          <description>Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants who received at least 1 dose of vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="112"/>
                <count group_id="O6" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="42.3"/>
                    <measurement group_id="O4" value="15.1"/>
                    <measurement group_id="O5" value="43.7"/>
                    <measurement group_id="O6" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness - Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="4.1"/>
                    <measurement group_id="O4" value="3.5"/>
                    <measurement group_id="O5" value="4.1"/>
                    <measurement group_id="O6" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0"/>
                    <measurement group_id="O2" value="44.5"/>
                    <measurement group_id="O3" value="36.9"/>
                    <measurement group_id="O4" value="32.2"/>
                    <measurement group_id="O5" value="41.0"/>
                    <measurement group_id="O6" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="36.7"/>
                    <measurement group_id="O3" value="28.2"/>
                    <measurement group_id="O4" value="28.7"/>
                    <measurement group_id="O5" value="36.2"/>
                    <measurement group_id="O6" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="24.8"/>
                    <measurement group_id="O3" value="20.3"/>
                    <measurement group_id="O4" value="14.0"/>
                    <measurement group_id="O5" value="12.1"/>
                    <measurement group_id="O6" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="70.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="46.0"/>
                    <measurement group_id="O5" value="54.7"/>
                    <measurement group_id="O6" value="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9"/>
                    <measurement group_id="O2" value="55.5"/>
                    <measurement group_id="O3" value="37.4"/>
                    <measurement group_id="O4" value="40.2"/>
                    <measurement group_id="O5" value="44.7"/>
                    <measurement group_id="O6" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="38.2"/>
                    <measurement group_id="O3" value="25.7"/>
                    <measurement group_id="O4" value="9.3"/>
                    <measurement group_id="O5" value="25.5"/>
                    <measurement group_id="O6" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
        <description>Systemic events (fever ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all subjects who received at least 1 dose of vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 - Dose 1</title>
            <description>Participants 7 to less than (&lt;) 12 months of age with 0 prior doses of Prevnar received a single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC)(infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 - Dose 1</title>
            <description>Participants 12 to &lt; 24 months of age with 0 prior doses of Prevnar received a single IM 0.5 mL doses of 13vPnC (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 - Dose 1</title>
            <description>Participants 24 to &lt; 72 months of age with 0 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series).</description>
          </group>
          <group group_id="O4">
            <title>13vPnC Group 1 - Dose 2</title>
            <description>Participants 7 to less than (&lt;) 12 months of age received a second single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days after the first (infant series).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Group 2 - Dose 2</title>
            <description>Participants 12 to &lt; 24 months of age received a second single IM 0.5 mL doses of 13vPnC at least 56 days from the first (infant series).</description>
          </group>
          <group group_id="O6">
            <title>13vPnC Group 1 - Dose 3</title>
            <description>Participants received a third single IM 0.5 mL dose of 13vPnC at 12 to 16 months of age (toddler dose), at least 46 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
          <description>Systemic events (fever ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>The safety population included all subjects who received at least 1 dose of vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="112"/>
                <count group_id="O6" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38°C but ≤39°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="8.1"/>
                    <measurement group_id="O5" value="5.1"/>
                    <measurement group_id="O6" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39°C but ≤40°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="2.3"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="22.2"/>
                    <measurement group_id="O3" value="16.3"/>
                    <measurement group_id="O4" value="17.2"/>
                    <measurement group_id="O5" value="25.5"/>
                    <measurement group_id="O6" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="30.6"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="34.5"/>
                    <measurement group_id="O5" value="34.0"/>
                    <measurement group_id="O6" value="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="13.0"/>
                    <measurement group_id="O3" value="11.6"/>
                    <measurement group_id="O4" value="9.3"/>
                    <measurement group_id="O5" value="10.1"/>
                    <measurement group_id="O6" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="19.4"/>
                    <measurement group_id="O3" value="6.8"/>
                    <measurement group_id="O4" value="18.4"/>
                    <measurement group_id="O5" value="20.4"/>
                    <measurement group_id="O6" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of antipyretic medication to treat symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="10.1"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="9.3"/>
                    <measurement group_id="O5" value="13.3"/>
                    <measurement group_id="O6" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of antipyretic medication to prevent symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="4.7"/>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O6" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration (GMC) After Vaccination in 13vPnC Groups</title>
        <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>28 to 42 days after vaccination 3 for Group 1 (13 to &lt;17 months of age), after vaccination 2 for Group 2 (14 to &lt;26 months of age), and after vaccination 1 for Group 3 (26 to &lt;73 months of age).</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC 7 to &lt;12 Months of Age</title>
            <description>Participants 7 to less than (&lt;) 12 months of age with 0 prior doses of 7-valent pneumococcal conjugate vaccine (Prevnar) received a total of 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC); the first two at least 28 days apart (infant series) and the third single IM 0.5 mL dose of 13vPnC at 12 to 16 months of age (toddler dose), at least 46 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC 12 to &lt;24 Months of Age</title>
            <description>Participants 12 to &lt; 24 months of age with 0 prior dose of 7-valent pneumococcal conjugate vaccine (Prevnar) received a total of 2 single IM 0.5 mL doses of 13vPnC at least 56 days apart.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC 24 to &lt; 72 Months of Age</title>
            <description>Participants 24 to &lt; 72 months of age with 0 prior doses of 7-valent pneumococcal conjugate vaccine (Prevnar) received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration (GMC) After Vaccination in 13vPnC Groups</title>
          <description>GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" lower_limit="3.11" upper_limit="4.23"/>
                    <measurement group_id="O2" value="4.28" lower_limit="3.78" upper_limit="4.86"/>
                    <measurement group_id="O3" value="3.37" lower_limit="2.95" upper_limit="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" lower_limit="3.90" upper_limit="5.84"/>
                    <measurement group_id="O2" value="3.38" lower_limit="2.81" upper_limit="4.06"/>
                    <measurement group_id="O3" value="3.41" lower_limit="2.80" upper_limit="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" lower_limit="2.21" upper_limit="2.96"/>
                    <measurement group_id="O2" value="3.08" lower_limit="2.69" upper_limit="3.53"/>
                    <measurement group_id="O3" value="2.67" lower_limit="2.32" upper_limit="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.04" lower_limit="6.95" upper_limit="9.30"/>
                    <measurement group_id="O2" value="6.45" lower_limit="5.48" upper_limit="7.59"/>
                    <measurement group_id="O3" value="2.24" lower_limit="1.71" upper_limit="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" lower_limit="2.39" upper_limit="3.23"/>
                    <measurement group_id="O2" value="3.71" lower_limit="3.29" upper_limit="4.19"/>
                    <measurement group_id="O3" value="2.56" lower_limit="2.17" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" lower_limit="2.35" upper_limit="3.54"/>
                    <measurement group_id="O2" value="3.07" lower_limit="2.68" upper_limit="3.51"/>
                    <measurement group_id="O3" value="2.53" lower_limit="2.14" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" lower_limit="1.82" upper_limit="2.55"/>
                    <measurement group_id="O2" value="1.98" lower_limit="1.64" upper_limit="2.39"/>
                    <measurement group_id="O3" value="1.55" lower_limit="1.31" upper_limit="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" lower_limit="2.44" upper_limit="3.39"/>
                    <measurement group_id="O2" value="2.74" lower_limit="2.37" upper_limit="3.16"/>
                    <measurement group_id="O3" value="1.78" lower_limit="1.52" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.68" upper_limit="2.24"/>
                    <measurement group_id="O2" value="1.86" lower_limit="1.60" upper_limit="2.15"/>
                    <measurement group_id="O3" value="1.42" lower_limit="1.23" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" lower_limit="2.34" upper_limit="3.46"/>
                    <measurement group_id="O2" value="2.16" lower_limit="1.89" upper_limit="2.47"/>
                    <measurement group_id="O3" value="2.33" lower_limit="2.05" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" lower_limit="3.12" upper_limit="4.45"/>
                    <measurement group_id="O2" value="2.62" lower_limit="2.25" upper_limit="3.06"/>
                    <measurement group_id="O3" value="2.96" lower_limit="2.52" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" lower_limit="4.54" upper_limit="6.18"/>
                    <measurement group_id="O2" value="5.99" lower_limit="5.40" upper_limit="6.65"/>
                    <measurement group_id="O3" value="4.92" lower_limit="4.26" upper_limit="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" lower_limit="4.28" upper_limit="5.33"/>
                    <measurement group_id="O2" value="4.94" lower_limit="4.31" upper_limit="5.65"/>
                    <measurement group_id="O3" value="6.03" lower_limit="5.22" upper_limit="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>13vPnC 7 to &lt;12 Months of Age</title>
          <description>Participants 7 to less than (&lt;) 12 months of age with 0 prior doses of 7-valent pneumococcal conjugate vaccine (Prevnar) received a total of 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC); the first two at least 28 days apart (infant series) and the third single IM 0.5 mL dose of 13vPnC at 12 to 16 months of age (toddler dose), at least 46 days after last infant dose.</description>
        </group>
        <group group_id="E2">
          <title>13vPnC 12 to &lt;24 Months of Age</title>
          <description>Participants 12 to &lt; 24 months of age with 0 prior dose of 7-valent pneumococcal conjugate vaccine (Prevnar) received a total of 2 single IM 0.5 mL doses of 13vPnC at least 56 days apart.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC 24 to &lt; 72 Months of Age</title>
          <description>Participants 24 to &lt; 72 months of age with 0 prior doses of 7-valent pneumococcal conjugate vaccine (Prevnar) received a single IM 0.5 mL dose of 13vPnC.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chalazion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <description>Infant Series Dose 1; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <description>Infant Series Dose 2; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <description>Infant Series Dose 3; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <description>Infant Series Dose 1; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <description>Infant Series Dose 2; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <description>Infant Series Dose 3; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <description>Infant Series Dose 1; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <description>Infant Series Dose 2; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <description>Infant Series Dose 3; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <description>Infant Series Dose 1; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <description>Infant Series Dose 2; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <description>Infant Series Dose 3; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <description>Infant Series Dose 1; Irritability</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <description>Infant Series Dose 2; Irritability</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <description>Infant Series Dose 3; Irritability</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <description>Infant Series Dose 1; Increased sleep</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <description>Infant Series Dose 2; Increased sleep</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <description>Infant Series Dose 3; Increased sleep</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <description>Infant Series Dose 1; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <description>Infant Series Dose 2; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <description>Infant Series Dose 3; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to animal</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urological examination abnormal</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (any)</sub_title>
                <description>Infant Series Dose 1; Tenderness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (any)</sub_title>
                <description>Infant Series Dose 2; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (any)</sub_title>
                <description>Infant Series Dose 3; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (significant)</sub_title>
                <description>Infant Series Dose 1; Tenderness (significant)=present and interfered with limb movement.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (significant)</sub_title>
                <description>Infant Series Dose 2; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (significant)</sub_title>
                <description>Infant Series Dose 3; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (Any)</sub_title>
                <description>Infant Series Dose 1; Induration (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (Any)</sub_title>
                <description>Infant Series Dose 2; Induration (Any)</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (Any)</sub_title>
                <description>Infant Series Dose 3; Induration (Any)</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (mild)</sub_title>
                <description>Infant Series Dose 1; Induration (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (mild)</sub_title>
                <description>Infant Series Dose 2; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (mild)</sub_title>
                <description>Infant Series Dose 3; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (moderate)</sub_title>
                <description>Infant Series Dose 1; Induration (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (moderate)</sub_title>
                <description>Infant Series Dose 2; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (moderate)</sub_title>
                <description>Infant Series Dose 3; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (severe)</sub_title>
                <description>Infant Series Dose 1; Induration (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (severe)</sub_title>
                <description>Infant Series Dose 2; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Induration (severe)</sub_title>
                <description>Infant Series Dose 3; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (any)</sub_title>
                <description>Infant Series Dose 1; Erythema (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (any)</sub_title>
                <description>Infant Series Dose 2; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (any)</sub_title>
                <description>Infant Series Dose 3; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (Mild)</sub_title>
                <description>Infant Series Dose 1; Erythema (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (Mild)</sub_title>
                <description>Infant Series Dose 2; Erythema (Mild)</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (Mild)</sub_title>
                <description>Infant Series Dose 3; Erythema (Mild)</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (Moderate)</sub_title>
                <description>Infant Series Dose 1; Erythema(moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (Moderate)</sub_title>
                <description>Infant Series Dose 2; Erythema (Moderate)</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (Moderate)</sub_title>
                <description>Infant Series Dose 3; Erythema (Moderate)</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (Severe)</sub_title>
                <description>Infant Series Dose 1; Erythema (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (Severe)</sub_title>
                <description>Infant Series Dose 2; Erythema (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Erythema (Severe)</sub_title>
                <description>Infant Series Dose 3; Erythema (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

